Kura Oncology COO Sells 6,906 and 3,668 Shares

A September 28 sale covered taxes associated with vesting 1/6th of the underlying performance-based restricted stock unit shares.

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported direct sales of 6,906 common shares on September 28, 2026, at $10.4973 per share and 3,668 shares on September 29 at a weighted-average $10.7516 per share. The September 28 sale was a sell-to-cover for taxes associated with vesting 1/6th of the underlying shares of performance-based restricted stock units; the September 29 shares were acquired upon vesting of performance restricted stock units on September 27. The sales were effected under a Rule 10b5-1 trading plan adopted May 29, 2026.

Insider Trade Summary 10b5-1

Net Seller: 10,574 shares

Net Sell 2 txns

Insider FORD KATHLEEN

Role Chief Operating Officer

Sold 10,574 shs ($112K)

Type	Security	Shares	Price	Value
Sale	Common Stock F2, F3	3,668	$10.7516	$39K
Sale	Common Stock F1	6,906	$10.4973	$72K

Holdings After Transaction: Common Stock — 142,986 shares (Direct)

Footnotes (3)

1. F1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares.
2. F2. The shares sold were acquired by the Reporting Person upon vesting of performance restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
3. F3. This transaction was executed in multiple trades at prices ranging from $10.57 to $10.87. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 6,906 shares Sale price: $10.4973 per share Shares sold: 3,668 shares +3 more

6 metrics

Shares sold 6,906 shares September 28, 2026

Sale price $10.4973 per share September 28, 2026

Shares sold 3,668 shares September 29, 2026

Weighted-average sale price $10.7516 per share September 29, 2026

Underlying shares vesting 1/6th Performance-based restricted stock units; September 28 sale was for tax withholding

Rule 10b5-1 plan adoption May 29, 2026 Trading plan for the reported sales

Key Terms

performance-based restricted stock units, sell-to-cover, Rule 10b5-1 trading plan, weighted average sale price

4 terms

performance-based restricted stock units financial

"vesting of 1/6th of the underlying shares of performance-based restricted stock units"

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

sell-to-cover financial

"Sell-to-cover for taxes associated with the vesting"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KURA shares did Kathleen Ford sell, and at what prices?

Kathleen Ford sold 6,906 shares on September 28, 2026, at $10.4973 per share, and 3,668 shares on September 29, 2026, at a weighted-average sale price of $10.7516 per share. The September 29 trades ranged from $10.57 to $10.87.

Why were KURA shares sold on September 28?

The 6,906-share sale was described as a sell-to-cover for taxes associated with vesting 1/6th of the underlying shares of performance-based restricted stock units granted to Kathleen Ford on May 31, 2023. The one-year anniversary of the specified development milestone was determined to have been met on September 27, 2026.

Were Kathleen Ford's KURA sales made under a Rule 10b5-1 plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan that Kathleen Ford adopted on May 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 06:30 PM Accepted by SEC EDGAR 09/29/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FORD KATHLEEN

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/28/2026		S(1)		6,906	D	$10.4973	146,654	D
Common Stock	09/29/2026		S(2)		3,668	D	$10.7516(3)	142,986	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares.

2. The shares sold were acquired by the Reporting Person upon vesting of performance restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.

3. This transaction was executed in multiple trades at prices ranging from $10.57 to $10.87. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	Teresa Bair Attorney-in-fact for Kathleen Ford	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)